Fig. 6: Patient-derived mutations of PDK1 promote AKT1 activation and oncogenic functions.
From: S6K1-mediated phosphorylation of PDK1 impairs AKT kinase activity and oncogenic functions
a IB analysis of DLD1-PDK1 knockout cells stably infected with the indicated constructs. pT308-AKT/AKT1 ratio were calculated. (mean ± SD, n = 3), *P < 0.05, **P < 0.01. b, c Cells generated in a were subjected to colony formation and soft agar assays. (mean ± SD, n = 3) **P < 0.01. d, e Cells generated in a were subjected to mouse xenograft assays. Tumor sizes were monitored (d, P = 0.0045), and dissected tumors were weighed (e, P = 0.013, 0.008, 0.002, 0.003, 0.0003, 0.003). The Error bars in the d, e are mean plus or minus SD, n = 5 mice. *P < 0.05, **P < 0.01. f IB analysis of WCL derived from dissected tumor tissues. g pT308-AKT/AKT1 ratio in f were calculated, (mean ± SD, n = 3), *P < 0.05, **P < 0.01. Statistical significance was determined by two-tailed Student’s t-test in a, c, e, g and two-way ANOVA in d. *P < 0.05, **P < 0.01. Source data are provided in Source Data files. EV, empty vector. WCL, whole cell lysate. WT, wild type.
